EV Biologics (EV Biologics) Cash, Cash Equivalents, Marketable Securities : $8.39 Mil (As of Dec. 2017)

View and export this data going back to 2015. Start your Free Trial

What is EV Biologics Cash, Cash Equivalents, Marketable Securities?

EV Biologics's quarterly cash, cash equivalents, marketable securities declined from Dec. 2016 ($2.48 Mil) to Jun. 2017 ($1.81 Mil) but then increased from Jun. 2017 ($1.81 Mil) to Dec. 2017 ($8.39 Mil).

EV Biologics's annual cash, cash equivalents, marketable securities declined from Jun. 2015 ($16.47 Mil) to Jun. 2016 ($2.74 Mil) and declined from Jun. 2016 ($2.74 Mil) to Jun. 2017 ($1.81 Mil).

EV Biologics Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for EV Biologics's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EV Biologics Cash, Cash Equivalents, Marketable Securities Chart

EV Biologics Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

Cash, Cash Equivalents, Marketable Securities

5.79

19.73

16.47

2.74

1.81

EV Biologics Quarterly Data
	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Jun17	Dec17
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial												2.74	2.66	2.48	1.81	8.39

EV Biologics Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

EV Biologics (OTCPK:YECO) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

EV Biologics Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of EV Biologics's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

EV Biologics (EV Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EV Biologics Inc (OTCPK:YECO) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

XCNQ:NIRV ENVB BLCM NLSP BRTX ADTX XKRX:066830 ALLR XMAD:ADL ARTL

Traded in Other Exchanges

N/A

Address

1621 Central Avenue, Cheyenne, WY, USA, 82001

Website

https://www.evbiologics.com

EV Biologics Inc is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.

Executives

Daniel S Mckinney	director, 10 percent owner, officer: CEO	TWO IFC, 19TH FLOOR, 8 FINANCE STREET, CENTRAL, HONG KONG F4 000000
Michael W Harlan	director	C/O WASTE CONNECTIONS, INC., 610 APPLEWOOD CRESCENT, SUITE 200, VAUGHAN A6 L4K 0C3